LC
NMRA icon

Lunate Capital’s Neumora Therapeutics NMRA Stock Holding History

Lunate Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61M Hold
2,124,143
– – 1.84% 9
2026
Q1 		$4.14M Hold
2,124,143
– – 3.44% 4
2025
Q4 		$3.8M Hold
2,124,143
– – 1.44% 4
2025
Q3 		$3.87M Hold
2,124,143
– – 1.75% 5
2025
Q2 		$1.56M Hold
2,124,143
– – 0.87% 4
2025
Q1 		$2.12M Buy
+2,124,143
New +$3.64M 1.24% 4

Other funds holding NMRA

WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AH
Addis & Hill Wayne, Pennsylvania $181M AUM 21.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Lunate Capital's NMRA Position: Q2 2026 in Review

Lunate Capital held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 2,124,143 shares worth $3.61M. The position accounts for 1.84% of the portfolio, ranked #9.

Lunate Capital first reported a position in NMRA in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.14M in Q1 2026. 12 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Lunate Capital held 2,124,143 shares of Neumora Therapeutics worth $3.61M as of Q2 2026.
  • Lunate Capital left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up 1.84% of Lunate Capital's portfolio in Q2 2026, its #9 holding.
  • Lunate Capital first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Lunate Capital's Neumora Therapeutics position peaked at $4.14M in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Lunate Capital's 13F filing for Q2 2026, filed 23 Jul 2026.